Ultragenyx (RARE) announced that it has completed the rolling submission of its biologics license application to the FDA, seeking approval for DTX401 AAV gene therapy as a treatment for Glycogen Storage Disease Type Ia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: